Head-to-head · WeighScore
Belle Health vs Trimi
The verdict
Trimi takes it — 86.4/100 to 73.8/100.
Trimi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bottom-quartile pricing on both molecules under one flat membership, shipped free nationwide — a strong-value pick sitting just behind the top tier.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | Trimi |
|---|---|---|
| WeighScore | 73.8/100 | 86.4/100 |
| Grade | C | B |
| Site position | #75 | #4 |
| Semaglutide | From $109/mo (compounded; supply terms unverified) | $175/mo month-to-month · $99/mo only on a 12-month prepay ($1,188 in one charge) |
| Tirzepatide | From $179/mo (compounded; supply terms unverified) | $235/mo month-to-month · $125/mo only on a 12-month prepay ($1,500 in one charge) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #75 · C
FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.
Strengths
- Weekly live group sessions with a named registered dietitian are included
- Provider review, nurse support, injection supplies and shipping are included
- Advertises the same price across dose levels
- Terms state telehealth availability in all 50 states
Where it loses points
- Starting prices do not establish the required supply length, upfront charge or renewal amount
- Compounded medications are not FDA-approved finished products
- Prescription products are nonrefundable after shipment; subscriptions may renew automatically
- FDA issued Belle Health LLC dba Belle a warning letter in February 2026; the letter is public in FDA's warning-letter database
Site position #4 · B
Strengths
- Low flat pricing on both semaglutide and tirzepatide
- Both molecules on a single membership
- Free shipping to all 50 states
- Fast dispatch once the prescriber signs off
Where it loses points
- Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
- Injection only — no oral or sublingual route
- Dispensing pharmacy not publicly named
- Shorter public track record than the incumbents
Featured provider
Trimi
Trimi scores 86.4/100 (B). Bottom-quartile pricing on both molecules under one flat membership, shipped free nationwide — a strong-value pick sitting just behind the top tier.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.